Search for Clinical Trial Results

Sponsored By

Chediak-Higashi Syndrome - 13 Studies Found

Status Study
Recruiting Study Name: Study of Chediak-Higashi Syndrome
Condition: Chediak Higashi Syndrome
Date: 2000-06-16
Completed Study Name: Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related Disorders
Condition:
  • Chediak Higashi Syndrome
  • Chronic Granulomatous Disease
    • Date: 2000-07-04
Completed Study Name: Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
Condition:
  • Chediak-Higashi Syndrome
  • Graft Versus Host Disease
  • Date: 2000-07-05
    Interventions:
    • Drug: anti-thymocyte globulin
    • Drug: busulf
Terminated Study Name: Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Condition:
  • Immunologic Deficiency Syndromes
  • Chediak-Higashi Syndrome

    • Date: 2000-07-05
    Interventions:
    • Drug: anti-thymocyte globulin
    • Drug: busulf
Completed Study Name: Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
Condition:
  • Sickle Cell Disease
  • Thalassemia
  • Anemia
  • Thalassemia
  • Sickle Cell Disease
  • Glanzmann Thrombasthenia Date: 2010-09-15
    Interventions: Drug: Alefacept 0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacep
Completed Study Name: Stem Cell Transplant for Immunologic or Histiocytic Disorders
Condition:
  • Hemophagocytic Lymphohistiocytosis
  • X-Linked Lymphoproliferative Disorders
  • Procedure: Stem Cell Transplant

Completed Study Name: T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
Condition:
  • Hemophagocytic Lymphohistiocytosis
  • X-Linked Lymphoproliferative Disorders
  • Procedure: Stem Cell Transplant

Recruiting Study Name: BMT Abatacept for Non-Malignant Diseases
Condition:
  • Hurler Syndrome
  • Fanconi Anemia
  • Glanzmann Thrombasthenia Date: 2013-07-24
    Interventions: Drug: Abatacept All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis
Recruiting Study Name: Immune Disorder HSCT Protocol
Condition: